More interesting discoveries from the RV144 trial (Tweeted by ‏@TweetSosa )

A recent paper by a multi-center group looking into the famous "31.2% vaccine efficacy" study (RV144 trial) shows interesting features associated with this protection against HIV-1.

Shuying Li looked at vaccine-induced Fc receptor-mediated antibody function and in this paper, show that a single nucleotide polymorphism in the FcR-encoding genes is strongly associated with protection. Individuals with a  SNP (rs114945036) carrying CC in this SNP had a vaccine efficacy of 15% while those with a CT or TT had a vaccine efficacy of 91% against HIV-1 subtype CRF01_AE with a lysine at position 169 (169K) in the V2 loop.

RV144 is a treasure trove of discoveries.

The world is eagerly waiting for more data and a cure!


This has been tweeted:
 21m
In Study of HIV Vaccine Trial Subjects, Genotype Defines Subsets with Strong and Weak Response

Comments

Post a Comment

Popular posts from this blog

Coronavirus and Vaccine Development

Coronavirus Vaccine Update: In addition to VBI Vaccines Inc. (Ottawa, Canada), the following firms are as of 27 March 2020 beginning Phase 1 testing Phase I vaccine candidates   Company:  Moderna Vaccine candidate:  mRNA-1273 Details:  Moderna is the Massachusetts-based biotech company behind mRNA-1273, a vaccine candidate developed using prior studies of related coronaviruses, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Study Design:  A Phase 1, open-label, dose-ranging clinical trial of 45 healthy participants between 18-55 years old Institution:   Kaiser Permanente Washington Health Research Institute Status:  Recruiting completed 19 March 2020 ClinicalTrials.gov Identifier:   NCT04283461 Funding:  NIAID   Company:  CanSino Biologics Vaccine candidate:  Ad5-nCoV Details:  China’s CanSino Biologics has developed a recombinant novel coronavirus vaccine that incorporates...
Read more

Absurd claims by the Nation of Islam regarding Ebola?

A recent article found on finalcall.com is making the rounds on social media.  In a nutshell, the Minister of the Nation of Islam claims that the western world conducted a massive clinical trial of an Ebola vaccine just before the latest  outbreak in West Africa that killed several thousands. Again conspiracy theorists are out to make Ebola as a man-made disaster that is killing Africans. There are some true facts in the story, particularly those about ZMapp being made available to a select few and not available to a large number of patients, especially poor Africans! It would have created quite an outrage if the ZMapp antibody was administered to poor Africans and many died!! The fact that it was tried on some Americans point to the fact that ZMapp did not want to be named and shamed as a company that uses poor Africans as guinea pigs. It is pathetic that scientific facts are not debated intelligently before publication in obscure publications that promote conspiracy theor...
Read more

RV144: New discoveries from Old Trials.

There have been a series of papers describing the " Antibody Profile " of participants in the partially successful RV144 Trial that I had described earlier. The first paper looking at the antibody type is a paper by Nicole Yates that appeared in Science Trans Med (2014) . Very little is known about the protective role of vaccine-induced IgG3 antibodies for HIV-1. Previously, it was found that a best known anti-HIV-1 antibody, 2F5, is of IgG3 origin. In the paper by Yates et al., they compared antibody profiles of RV144 trial and the VAX003 trial, which was a modification of the RV144 vaccine. Background: RV144 consists of (cladeB/E) ALVAC prime plus 2 protein boosts rgp120 boost VAX003: consists of (cladeB/E) gp120 protein immunogen. Results: *It was found that IgG3 response rates were significantly higher in RV144 compared to VAX003 at peak immunogenicity time point. **V1-V2 IgG3 antibodies correlated with decreased risk of infection in RV144. ...
Read more